Russian researchers presented an interesting development – express hemotest assessing the risk of ischaemic stroke of brain at Asian Entrepreneurship Award (Tokyo).
The development belongs to Diagnostic Reagents & Devices, DRD, LLC – a resident of technology hub at Skolkovo. It deals with development and marketing of diagnostic devices – express hemotests, based on innovative bio- and IT-technologies.
The project ranked second at the award, and researchers got a prize worth 500 thos. Yens.
The proposed test for NR2 antibodies is designed to detect isolated or repeated ischaemic stroke and increased risk of ischaemic events in brain of patients with concomitant disorders. To assess the risk of stroke NR2 antibody – a specific biomarker bound to receptors at the surface of brain microvessels was chosen. The level of biomarker is increased, as microischaemic events occur in the brain, signaling potential stroke. Having a warning one may take early preventive measures.
Technical and analytical studies of the innovative product are pending. If passed successfully, medical use of the development can be discussed.